

REGISTERED NUMBER: 09566234 (England and Wales)

Financial Statements for the Year Ended 31 December 2018

for

Tanner Pharma UK Limited

Contents of the Financial Statements
for the Year Ended 31 December 2018

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	4

DIRECTOR:

Mr R F Bourne

REGISTERED OFFICE:

2 Adelaide Street
St Albans
Hertfordshire
AL3 5BH

REGISTERED NUMBER:

09566234 (England and Wales)

ACCOUNTANTS:

Visionary Accountants
2 Adelaide Street
St Albans
Hertfordshire
AL3 5BH

Balance Sheet
31 December 2018

	Notes	31.12.18 £	£	31.12.17 £	£
FIXED ASSETS					
Tangible assets	4		37,482		46,831
Investments	5		<u>16,356</u>		<u>16,356</u>
			53,838		63,187
CURRENT ASSETS					
Stocks		165,663		25,586	
Debtors	6	639,403		314,056	
Cash at bank		<u>217,579</u>		<u>14,523</u>	
		1,022,645		354,165	
CREDITORS					
Amounts falling due within one year	7	<u>2,245,167</u>		<u>1,440,536</u>	
NET CURRENT LIABILITIES			<u>(1,222,522)</u>		<u>(1,086,371)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			(1,168,684)		(1,023,184)
CREDITORS					
Amounts falling due after more than one year	8		<u>1,019,333</u>		<u>499,571</u>
NET LIABILITIES			<u>(2,188,017)</u>		<u>(1,522,755)</u>
CAPITAL AND RESERVES					
Called up share capital			62,500		62,500
Retained earnings			<u>(2,250,517)</u>		<u>(1,585,255)</u>
SHAREHOLDERS' FUNDS			<u>(2,188,017)</u>		<u>(1,522,755)</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2018 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395
- (b) and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director on 17 September 2019 and were signed by:

Mr R F Bourne - Director

Notes to the Financial Statements
for the Year Ended 31 December 2018

1. **STATUTORY INFORMATION**

Tanner Pharma UK Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. **ACCOUNTING POLICIES**

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - 33% on cost and 15% on cost

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

3. **EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 15 (2017 - 14).

Notes to the Financial Statements - continued
for the Year Ended 31 December 2018

4. **TANGIBLE FIXED ASSETS**

	Plant and machinery etc £
COST	
At 1 January 2018	63,348
Additions	<u>7,209</u>
At 31 December 2018	<u>70,557</u>
DEPRECIATION	
At 1 January 2018	16,517
Charge for year	<u>16,558</u>
At 31 December 2018	<u>33,075</u>
NET BOOK VALUE	
At 31 December 2018	<u>37,482</u>
At 31 December 2017	<u>46,831</u>

5. **FIXED ASSET INVESTMENTS**

	Shares in group undertakings £
COST	
At 1 January 2018 and 31 December 2018	<u>16,356</u>
NET BOOK VALUE	
At 31 December 2018	<u>16,356</u>
At 31 December 2017	<u>16,356</u>

The fixed asset investments held are shares in Tanner Pharma CH GmbH consisting of 200 shares at CHF 100 each totalling CHF 20,000. Tanner Pharma UK Limited is a 100% shareholder of Tanner Pharma CH GmbH. This investment was realised on 9th November 2016 and an exchange rate of CHF 1 to £0.8178 was used.

6. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.18 £	31.12.17 £
Trade debtors	577,969	269,309
Amounts owed by group undertakings	19,181	19,181
Other debtors	<u>42,253</u>	<u>25,566</u>
	<u>639,403</u>	<u>314,056</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2018

7. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.18	31.12.17
	£	£
Payments on account	740,274	8,089
Trade creditors	134,283	49,285
Amounts owed to associates	1,144,213	986,634
Taxation and social security	36,846	42,627
Other creditors	189,551	353,901
	<u>2,245,167</u>	<u>1,440,536</u>

8. **CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**

	31.12.18	31.12.17
	£	£
Amounts owed to group undertakings	<u>1,019,333</u>	<u>499,571</u>

9. **RELATED PARTY DISCLOSURES**

Tannergap INC

A company in which Mr R F Bourne is a shareholder.

The total amount outstanding at the year end due back to Tannergap Inc was £1,144,213 (2017 - £986,634). This loan is unsecured, interest free and repayable on demand.

Tannerlac UK Limited

A company in which Tanner Pharma UK Limited is 100% shareholder.

At the year end Tannerlac UK Limited owed Tanner Pharma UK Limited £19,181 (2017 - £19,181). This loan is unsecured, interest free and repayable on demand.

Tanner Pharma CH GmbH

A company in which Mr R F Bourne is a director.

At the year end Tanner Pharma UK Limited owed Tanner Pharma CH GmbH £1,019,333 (2017 - £499,571). This loan is unsecured and repayable on the day prior to the fifth anniversary of the effective date or such earlier or later date as may be agreed between the Borrower and the Lender. There is interest of 2.5% charged on the loan. Interest has been accrued and will be released when the loan is repaid.

10. **ULTIMATE CONTROLLING PARTY**

The ultimate controlling party is Mr R F Bourne.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.